SNGX READ THE FULL SNGX RESEARCH REPORT Business Update DMC Confirms No Safety Concerns for Ongoing Phase 3 FLASH2 Trial On ...
The hybrid model is emerging as the framework for trustworthy AI in test analytics. It retains traceability and supports ...
Guggenheim Securities 2nd Annual Healthcare Innovation Conference November 10, 2025 9:30 AM ESTCompany ParticipantsAaron ...
Discusses Positive Phase 3 PEAK Trial Results of Bezuclastinib in Gastrointestinal Stromal Tumors November 8:00 ...
Zoltán Kaló and colleagues consider approaches to counter systemic inequities and power imbalances arising from discrete national policies for drug pricing and reimbursement Current pricing mechanisms ...
Year, and Adjusted EBITDA of $11.7 Million, up 34% Year-Over YearNine Month Revenue of $135.8 Million, up 11% Year-over-Year; Adjusted EBITDA ...
PTEN mutations are enriched in the SHH-1 subtype that has the lowest survival rate. Widespread heterozygous loss of Pten in two SHH-MB mouse models increases penetrance and excellerates onset of ...
One of the most common genetic diseases, AATD, involves the retention of misfolded alpha 1 antitrypsin (AAT) in hepatocytes, ...
Evaluation: Healthcare AI must surpass accuracy metrics to establish clinical validity, safety, and suitability for diverse ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback